OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Headache and Pain is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
CGRP-dependent sensitization of PKC-δ positive neurons in central amygdala mediates chronic migraine	559
Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis	277
Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II	125
Real-World experience of interictal burden and treatment in migraine: a qualitative interview study	101
Migraine susceptibility is modulated by food triggers and analgesic overuse via sulfotransferase inhibition	89
Using natural language processing to automatically classify written self-reported narratives by patients with migraine or cluster headache	71
Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation	67
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials	65
Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States	64
Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency	61
The relationship between headache-attributed disability and lost productivity: 2. Empirical evidence from population-based studies in nine disparate countries	60
Trigeminal ganglion itself can be a viable target to manage trigeminal neuralgia	60
Debate: Are cluster headache and migraine distinct headache disorders?	53
Visual stimulation and frequency of focal neurological symptoms engage distinctive neurocognitive resources in migraine with aura patients: a study of resting-state functional networks	52
Age- and frequency-dependent changes in dynamic contrast perception in visual snow syndrome	49
Characteristics of N400 component elicited in patients who have migraine with aura	48
Diagnostic criteria for acute headache attributed to ischemic stroke and for sentinel headache before ischemic stroke	47
CGRP and PACAP-38 play an important role in diagnosing pediatric migraine	45
Abnormalities in resting-state EEG microstates are a vulnerability marker of migraine	43
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients	42
Dopamine receptor D2 regulates GLUA1-containing AMPA receptor trafficking and central sensitization through the PI3K signaling pathway in a male rat model of chronic migraine	39
Pre-pregnancy migraine diagnosis, medication use, and spontaneous abortion: a prospective cohort study	38
Similarities and differences between SUNCT and SUNA: a cross-sectional, multicentre study of 76 patients in China	37
Measuring interictal burden among people affected by migraine: a descriptive survey study	36
Hypoperfusion in nucleus accumbens in chronic migraine using 3D pseudo-continuous arterial spin labeling imaging MRI	36

Total tenderness score and pressure pain thresholds in persistent post-traumatic headache attributed to mild traumatic brain injury	34
A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United States	34
One-quarter of individuals with weekly headache have never consulted a medical doctor: a Danish nationwide cross-sectional survey	33
Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results	32
Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study	32
Migraine epidemiology and comorbidities in Southern Israel: a clinical database study in a universal health coverage setting	31
Attenuated alpha oscillation and hyperresponsiveness reveals impaired perceptual learning in migraineurs	31
Gamma-aminobutyric acid and glutamate/glutamine levels in the dentate nucleus and periaqueductal gray with episodic and chronic migraine: a proton magnetic resonance spectroscopy study	30
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study	30
Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany	30
Which is the best transcranial direct current stimulation protocol for migraine prevention? A systematic review and critical appraisal of randomized controlled trials	30
HMGB1 in the mPFC governs comorbid anxiety in neuropathic pain	30
Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phas	29
The headache registry of the German Migraine and Headache Society (DMKG): baseline data of the first 1,351 patients	28
Development and validation of a novel model for characterizing migraine outcomes within real-world data	28
Altered effective connectivity in migraine patients during emotional stimuli: a multi-frequency magnetoencephalography study	28
Cerebral blood flow alterations in migraine patients with and without aura: An arterial spin labeling study	28
De novo headache in ischemic stroke patients treated with thrombectomy: a prospective study	27
Sphingosine-1 phosphate receptor 1 contributes to central sensitization in recurrent nitroglycerin-induced chronic migraine model	27
Tracking the evolution of non-headache symptoms through the migraine attack	27
Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies	27
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study	26
Pre-attack and pre-episode symptoms in cluster headache: a multicenter cross-sectional study of 327 Chinese patients	26
Major sex differences in migraine prevalence among occupational categories: a cross-sectional study using UK Biobank	26